| Literature DB >> 34465585 |
Megann A Boone1,2, Cenny Taslim2, Jesse C Crow2, Julia Selich-Anderson2, Mike Watson3, Peter Heppner4, James Hamill4, Andrew C Wood4,5, Stephen L Lessnick6,2,7, Mark Winstanley4,5.
Abstract
Ewing sarcoma is a pediatric bone cancer defined by a chromosomal translocation fusing one of the FET family members to an ETS transcription factor. There have been seven reported chromosomal translocations, with the most recent reported over a decade ago. We now report a novel FET/ETS translocation involving FUS and ETV4 detected in a patient with Ewing sarcoma. Here, we characterized FUS/ETV4 by performing genomic localization and transcriptional regulatory studies on numerous FET/ETS fusions in a Ewing sarcoma cellular model. Through this comparative analysis, we demonstrate significant similarities across these fusions, and in doing so, validate FUS/ETV4 as a bona fide Ewing sarcoma translocation. This study presents the first genomic comparison of Ewing sarcoma-associated translocations and reveals that the FET/ETS fusions share highly similar, but not identical, genomic localization and transcriptional regulation patterns. These data strengthen the notion that FET/ETS fusions are key drivers of, and thus pathognomonic for, Ewing sarcoma. IMPLICATIONS: Identification and initial characterization of the novel Ewing sarcoma fusion, FUS/ETV4, expands the family of Ewing fusions and extends the diagnostic possibilities for this aggressive tumor of adolescents and young adults. ©2021 The Authors; Published by the American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34465585 PMCID: PMC8568690 DOI: 10.1158/1541-7786.MCR-21-0354
Source DB: PubMed Journal: Mol Cancer Res ISSN: 1541-7786 Impact factor: 6.333